The KLASH Study: Dysregulation of the Soluble α-Klotho-FGF23 Axis in Hashimoto's Thyroiditis - A Prospective Case-Control Study
| Registry | NCT07453290, acronym klofgfhashi |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 150 (Estimated) |
| Sponsor | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital (Other) |
| Conditions | Autoimmune Thyroiditis |
| Interventions | Blood Sampling and Biomarker Measurement (Other) |
| Dates | start 2026-03-02 (estimated), primary completion 2026-05-20 (estimated), completion 2026-05-20 (estimated), first posted 2026-03-05, last updated 2026-03-05 |
Related Papers Related Patents Related Grants Related Experts
All trials for Autoimmune Thyroiditis All trials of Blood Sampling and Biomarker Measurement
Hashimoto's thyroiditis (HT) is the most common autoimmune thyroid disease and is increasingly recognized as a condition associated with chronic low-grade systemic inflammation beyond thyroid hormone dysfunction. The soluble α-Klotho-fibroblast growth factor 23 (FGF23) axis plays a central role in mineral metabolism, inflammation, and aging-related pathways; however, its involvement in HT has not been adequately characterized.
This prospective case-control study aims to compare serum soluble α-Klotho and FGF23 levels between adults with Hashimoto's thyroiditis and age- and sex-matched healthy controls, and to investigate their associations with thyroid function parameters, inflammatory markers, and autoimmune burden. In addition, the FGF23/sKlotho ratio will be evaluated as an integrated marker of functional imbalance within the Klotho-FGF23 axis.
The study seeks to determine whether Hashimoto's thyroiditis is associated with systemic dysregulation of the Klotho-FGF23 pathway independent of renal function and mineral metabolism.
Hashimoto's thyroiditis (HT) is a chronic autoimmune disease characterized by lymphocytic infiltration of the thyroid gland and the presence of anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin (anti-TG) antibodies. While traditionally defined by thyroid hormone dysfunction, emerging evidence suggests that HT is associated with persistent immune activation, oxidative stress, and low-grade systemic inflammation.
The α-Klotho-FGF23 axis is an endocrine pathway involved in phosphate metabolism, vitamin D regulation, inflammation, and aging-related biological processes. Soluble α-Klotho (sKlotho) exerts anti-inflammatory and anti-oxidative effects, whereas FGF23 is increasingly recognized as a hormone influenced by inflammatory stimuli. Dysregulation of this axis has been reported in various chronic inflammatory conditions; however, data in autoimmune thyroid disease are limited.
This prospective, single-center case-control study will include adult patients with Hashimoto's thyroiditis and healthy controls without thyroid or systemic autoimmune disease. Serum soluble α-Klotho and FGF23 levels will be measured using enzyme-linked immunosorbent assay (ELISA). Clinical data including thyroid function tests (TSH, free T4), thyroid autoantibodies (anti-TPO, anti-TG), renal function parameters, mineral metabolism markers (calcium, phosphorus, 25-hydroxyvitamin D), and C-reactive protein (CRP) will be recorded.
Primary analyses will compare sKlotho and FGF23 levels between groups. Secondary analyses will evaluate associations between these biomarkers and autoimmune burden (anti-TG levels), inflammatory status (CRP), and thyroid function. Multivariable regression models will be used to determine independent associations after adjustment for potential confounders.
The study also aims to evaluate the FGF23/sKlotho ratio as an integrated indicator of functional imbalance within the Klotho-FGF23 axis in Hashimoto's thyroiditis.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Hashimoto Disease | Other: Blood Sampling and Biomarker Measurement | Adults aged 18-65 years diagnosed with Hashimoto's thyroiditis based on clinical evaluation, thyroid function tests, and positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies. Participants may be euthyroid or hypothyroid. Serum soluble α-Klotho and FGF23 levels will be measured. Clinical, inflammatory, renal, and mineral metabolism parameters will be recorded. | |
| Healthy Controls | Other: Blood Sampling and Biomarker Measurement | Age- and sex-matched adults without a history of thyroid disease, autoimmune disorders, chronic kidney disease, or chronic systemic illness. Participants will have normal thyroid function tests. Serum soluble α-Klotho and FGF23 levels will be measured, and clinical laboratory parameters will be recorded for comparison. |
Sex: All, ages: 18 Years to 80 Years
Inclusion Criteria: Adults aged 18-65 years Ability to provide written informed consent Hashimoto group: Diagnosis of Hashimoto's thyroiditis based on positive anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) antibodies with compatible clinical/ultrasound findings (as available) Control group: No history of thyroid disease or autoimmune disease; normal thyroid function tests (TSH and free T4 within reference range) Exclusion Criteria: Pregnancy or breastfeeding Known chronic kidney disease (eGFR < 60 mL/min/1.73 m²) Active infection or acute inflammatory condition within the past 4 weeks Known malignancy under active treatment Chronic inflammatory/autoimmune disease other than Hashimoto's thyroiditis (e.g., rheumatoid arthritis, SLE, IBD) Use of systemic glucocorticoids or immunosuppressive therapy within the past 3 months Known parathyroid disease or disorders of calcium/phosphate metabolism Current use of medications strongly affecting mineral metabolism (e.g., phosphate binders, active vitamin D analogs)